Interestingly, this phenomenon mirrors the findings in ovarian clear cell carcinoma, where ARID1A mutations are associated with promoter hypermethylation and transcriptional repression of downstream targets such as IRX1, TMEM101, and TRIP6 (Li et al., 2024). The gene discussed is TMEM101; the disease is ovarian clear cell cancer.